Grifols, S.A.
GIFLF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.18B
Close$
$31.25
196.2% upside
Current Fair Value
196.2% upsideUndervalued by 196.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $7.18 Billion |
|---|---|
| Enterprise Value | $15.28 Billion |
| Annual dividend | $0.09 |
| Dividend yield | 0.75% |
| Earnings per Share | $0.59 |
| Beta | 1.19 |
| Outstanding Shares | 680,575,312 |
Return
| Return on Equity | 8.16% |
|---|---|
| Return on Assets | 2.25% |
| Return on Invested Capital | 7.45% |
Valuation & Multiples
| P/E Ratio | 16.38 |
|---|---|
| PEG | 51.91 |
| Price to Sales | 1.06 |
| Price to Book Ratio | 0.96 |
| Enterprise Value to Revenue | 2.06 |
| Enterprise Value to EBIT | 11.48 |
| Enterprise Value to Net Income | 33 |
| Total Debt to Enterprise | 0.56 |
| Debt to Equity | 1.55 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 28, 2026
EPS Estimate
$0.26
Consensus analyst estimateRevenue Estimate
$2.16 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$0.32
Consensus analyst estimateRevenue Estimate
$2.23 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Grifols SA
25,258 employees
CEO: Jose Ignacio Abia Buenache
Grifols, S.A., a company established in Barcelona, Spain, in 1940, specializes in the sourcing, production, and sale of therapeutic products, principally derived from blood plasma. Its diverse activities are structured across five main d...